Amgen (AMGN) to Release Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN) will likely be releasing its Q4 2025 results after the market closes on Tuesday, February 3rd. Analysts expect the company to announce earnings of $4.74 per share and revenue of $9.4558 billion for the quarter. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 3, 2026 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the previous year, the business earned $5.58 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $349.69 on Tuesday. Amgen has a 12-month low of $261.43 and a 12-month high of $350.43. The company has a market cap of $188.30 billion, a P/E ratio of 27.02, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company’s fifty day moving average is $332.23 and its two-hundred day moving average is $308.04.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 73.57%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 over the last three months. Company insiders own 0.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AMGN. Sittner & Nelson LLC grew its holdings in shares of Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after acquiring an additional 30 shares in the last quarter. Apexium Financial LP boosted its stake in Amgen by 1.6% in the 3rd quarter. Apexium Financial LP now owns 2,582 shares of the medical research company’s stock valued at $729,000 after purchasing an additional 40 shares during the period. Binnacle Investments Inc raised its stake in Amgen by 26.1% in the 3rd quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock worth $59,000 after purchasing an additional 43 shares in the last quarter. Peloton Wealth Strategists grew its position in Amgen by 0.4% during the third quarter. Peloton Wealth Strategists now owns 11,525 shares of the medical research company’s stock worth $3,252,000 after buying an additional 47 shares in the last quarter. Finally, CYBER HORNET ETFs LLC raised its stake in Amgen by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 1,442 shares of the medical research company’s stock valued at $407,000 after purchasing an additional 48 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Daiwa Capital Markets increased their price objective on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. BMO Capital Markets lifted their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. HSBC reaffirmed a “buy” rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. Finally, UBS Group boosted their price target on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $339.71.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.